Compositions and methods for cell targeting therapies
AssigneeUMC Utrecht Holding B.V.
InventorsJürgen Herbert Ernst KUBALL, Zsolt SEBESTYEN, Dennis BERINGER, Anna VYBOROVA
Life of this patent
Estimating the term…
Abstract
Described herein are compositions and methods of treatment for identifying and clearing cell types expressing particular cell surface markers. In one embodiment, the composition comprises a polypeptide construct that selectively binds a J-configuration of CD277 on a target cell, wherein said polypeptide construct is expressed in an engineered cell.
Claims19
-187. (canceled)
A pharmaceutical composition comprising a polypeptide construct that selectively binds a J-configuration of CD277 on a target cell, and wherein said polypeptide construct is expressed in cell.
Method of treating cancer in a subject comprising providing to the subject an effective amount of a pharmaceutical composition comprising a polypeptide construct that selectively binds a J-configuration of CD277 on a target cell, and wherein said polypeptide construct is expressed in cell.
A method of predicting a positive therapeutic response in a subject to treatment with a polypeptide construct capable of recognizing CD277, or an engineered cell expressing the polypeptide construct, the method comprising steps a) and b) or steps c), d) and e):
- a) identifying target cells of the patient as having a nucleotide sequence polymorphism associated with the activity of RhoB;
- and
- b) predicting the subject to exhibit the positive therapeutic response based on said identifying the target cells as having the nucleotide sequence polymorphism,
- or
- c) obtaining from the subject target cells expressing the CD277 molecule;
- d) identifying a J-configuration of the CD277 molecule expressed in the target cells;
- and
- e) predicting the subject to exhibit the positive therapeutic response based on said identifying the J-configuration of the CD277 molecule.
Dependencies are inferred from the claim text.